ProCE Banner Activity

CME

Breakthrough Therapeutics for CLL and Other B-Cell Malignancies: Focus on BTK Inhibitors From Development to Clinical Integration

Video

Watch this on-demand webcast from an ASH satellite symposium on the use of novel BTK inhibitors for patients with CLL and MCL, including discussions on current and emerging BTK inhibitors and combinations, treatment for frontline and relapsed/refractory CLL/SLL and MCL, toxicity management, and ongoing clinical trials.

Physicians: Maximum of 2.00 AMA PRA Category 1 Credits

Released: January 31, 2023

Expiration: January 30, 2024

No longer available for credit.

Share

Faculty

Jeff DONOTUSESharman

Jeff DONOTUSESharman, MD

Medical Director of Hematology Research
Willamette Valley Cancer Institute
US Oncology
Eugene, Oregon

Ian W. Flinn

Ian W. Flinn, MD, PhD

Director
Lymphoma Research Program
Sarah Cannon Research Institute
Program Director
Sarah Cannon Center for Blood Cancer
Tennessee Oncology
Nashville, Tennessee

Susan M. O'Brien

Susan M. O'Brien, MD

Professor
Division of Hematology/Oncology
School of Medicine
University of California, Irvine
Orange, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

BeiGene Ltd

Lilly

Target Audience

This program is intended for physicians and other healthcare professionals who care for patients with CLL/SLL or MCL.

Program Learning Goal

The goal of this activity is to improve the knowledge, competence, and confidence of learners to apply practice-changing clinical data and expert recommendations in order to optimize the use of current and emerging therapeutic strategies with BTKi in the care of their patients with CLL/SLL and MCL.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Compare first-generation and next-generation BTK inhibitors in terms of molecular characteristics, binding, targeted selectivity, approved indications, dosing, safety profile, and efficacy

  • Plan BTK inhibitor–based therapeutic strategies for treatment-naive patients with CLL/SLL or MCL, taking into consideration guidelines, expert recommendation, and recent practice-changing clinical trial results

  • Select optimal therapy in R/R CLL/SLL or MCL following progression on or intolerance of first-line and subsequent therapies

  • Manage toxicities associated with BTK inhibitor therapy to support adherence, appropriate dosing, and treatment continuation and to maximize patient survival and quality of life
  • Identify patients eligible for ongoing clinical trials evaluating currently available and emerging BTK inhibitors and BTK inhibitor–based combinations

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Jeff Sharman, MD: consultant/advisor/speaker: AbbVie, ADC Therapeutics, AstraZeneca, BeiGene, Bristol Myers Squibb, Genentech, Lilly, Merck.

Ian W. Flinn, MD, PhD: consultant (paid to institution): AbbVie, AstraZeneca, BeiGene, Century Therapeutics, Genentech, Genmab, Hutchison MediPharma, Iksuda, InnoCare Pharma, Janssen, Kite, MorphoSys, Myeloid Therapeutics, Novartis, Nurix, Pharmacyclics, Roche, Secura Bio, Servier, Takeda, TG Therapeutics, Verastem, Vincerx, Xencor; researcher (paid to institution): 2seventy bio, AbbVie, Acerta, Agios, ArQule, AstraZeneca, BeiGene, Biopath, Bristol-Myers Squibb, CALIBR, CALGB, Celgene, City of Hope National Medical Center, Constellation, Curis, CTI Biopharma, Epizyme, Fate Therapeutics, Forma, Forty Seven, Genentech, Gilead Sciences, InnoCare, IGM Biosciences, Incyte, Infinity, Janssen, Kite Pharma, Loxo, Merck, Millennium, MorphoSys, Myeloid Therapeutics, Novartis, Nurix, Pfizer, Pharmacyclics, Portola, Rhizen, Roche, Seattle Genetics, Tessa Therapeutics, TCR2 Therapeutics, TG Therapeutics, Trillium, Triphase Research & Development Corp, Unum Therapeutics, Verastem

Susan M. O’Brien, MD: consultant: AbbVie, Alexion, Amgen, Aptose Biosciences, Astellas, AstraZeneca, Autolus, Bristol Myers Squibb, Celgene, DynaMed, Gilead, GlaxoSmithKline, Janssen Oncology, Johnson & Johnson, Juno Therapeutics, Lilly, MEI Pharma, Merck, NOVA Research Company, Pfizer, Pharmacyclics, TG Therapeutics, Vaniam Group LLC, Verastem, Vida Ventures; researcher: Acerta, Alliance, BeiGene, Caribou Biosciences, Gilead, Kite, Loxo Oncology, Mustang, Nurix Therapeutics, Pfizer, Pharmacyclics, Regeneron, TG Therapeutics.

Kelly Brandt, PharmD, has no relevant financial relationships to disclose.

Gordon Kelley has no relevant financial relationships to disclose.

Timothy A. Quill, PhD, has no relevant financial relationships to disclose.

Krista Marcello has no relevant financial relationships to disclose.

Kevin Obholz, PhD, has no relevant financial relationships to disclose.

Kristen Rosenthal, PhD, has no relevant financial relationships to disclose.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 2.0 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 31, 2023, through January 30, 2024:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement
Joint AccreditationIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 

 

Physician Continuing Medical Education Credit Designation

Credit Designation
CCO designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.